E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/13/2011 in the Prospect News PIPE Daily.

Amarantus BioSciences could raise $10 million through equity financing

Financing agreement negotiated with investor Centurion Private Equity

By Devika Patel

Knoxville, Tenn., Oct. 13 - Amarantus BioSciences, Inc. said it settled a $10 million equity funding facility with Centurion Private Equity, LLC.

The three-year deal will be conducted in tranches of up to $750,000.

"This equity funding facility provided by Centurion Private Equity is one of the most flexible financing tools available to public biotechnology companies seeking to raise capital," Amarantus' board of directors special advisor, Samuel Herschkowitz, said in a press release.

"Centurion's financings will provide the company with strategic capital to fund its development programs while maintaining working capital flexibility in various fundraising market conditions. We believe this facility will likely attract additional financing sources for the company seeking to leverage the value of this facility," Herschkowitz said.

Added company chairman and chief executive officer Martin D. Cleary: "The company intends to strategically draw down on this facility in a manner that protects the best interests of our shareholders and use the proceeds for core product development, material transactions such as licensing, mergers, acquisition and other relevant value-added business development opportunities."

The biotechnology company is based in Sunnyvale, Calif.

Issuer:Amarantus BioSciences, Inc.
Issue:Equity funding facility
Amount:$10 million
Tenor:Three years
Warrants:No
Investor:Centurion Private Equity, LLC
Settlement date:Oct. 13
Stock symbol:OTCBB: AMBS
Stock price:$0.17 at close Oct. 12
Market capitalization:$11.39 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.